What We're Reading: Page 153
Industry reads hand-picked by our editors
Jul 15, 2021
-
STAT
Woodcock: FDA may have misstepped before Alzheimer’s drug approval
-
Bloomberg
Moderna's Next Act Is Using mRNA vs. Flu, Zika, HIV, and Cancer
-
Axios
Dems hatch plan to pay for soft infrastructure with renegotiated drug prices
-
BioPharma Dive
A cancer drug startup banks new funds for NK cell therapy
Jul 14, 2021
-
CNN
Biden in standoff with Democratic senators over who should lead FDA
-
JAMA
Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective
-
The Washington Post
Biden to pick former West Virginia health official as nation’s drug czar
-
Reuters
Illumina, Grail deal faces full-scale EU antitrust probe
Jul 13, 2021
Jul 12, 2021
-
The Washington Post
Pfizer expected to brief U.S. officials in coming days on the need for a booster shot
-
The Wall Street Journal
Biogen Alzheimer’s Drug Will Exceed the $56,000 List Price for Many, Analysis Says
-
The New York Times
How Much Longer Can Martin Shkreli Control a Pharma Firm From Prison?
Jul 09, 2021
Jul 08, 2021
-
Axios
The drug pricing lawsuit that could blow up Medicare
-
The Wall Street Journal
Theranos Founder Elizabeth Holmes Renews Fight to Constrain Prosecutors
-
NBC News
Pharma giant's policy change will devastate local HIV-prevention clinics' efforts
-
Fierce Biotech
Eli Lilly taps Verge Genomics in ALS deal worth $25M upfront
Jul 07, 2021
-
Bloomberg
When Lifesaving Vaccines Become Profit Machines for Drugmakers
-
The Washington Post
The controversial approval of an Alzheimer’s drug reignites the battle over the underlying cause of the disease
-
The Wall Street Journal
Covid-19 Vaccine-Related Blood Clots Linked to Amino Acids in New Study
-
Reuters
Novartis to make Leqvio for U.S. in Austria to overcome FDA delay
Previous
